- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05665023
Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma
Single-arm Phase II Study of Bevacizumab Plus Modified FOLFIRINOX Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
This study is aimed at recurrent/metastatic/resectable patients who have received systemic chemotherapy of 2nd line or less. Excludes previously diagnosed mucinous tumors of gastrointestinal origin through upper and lower endoscopy and pathologic immunohistochemical staining.
Bevacizumab plus modified FOLFIRINOX drug is administered every 2 weeks. To prevent neutropenia fever during chemotherapy, pegteograstim is given 24 hours after chemotherapy.
The primary objective of this study is the objective response rate (ORR). The secondary objectives are progression-free survival (PFS) and disease control rate at 6 months after administration, disease control rate (DCR), overall survival (OS), drug safety, and quality of life improvement as assessed by patient questionnaires.
In addition, the investigators intend to explore biomarkers that can predict the effect of bevacizumab + mFOLFIRINOX combination therapy through the collection of tumor samples and blood samples for exploratory purposes.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Min Hwan Kim
- Phone Number: +82-2-2228-8133
- Email: gemgoon3691@yuhs.ac
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Yonsei University Health System, Severance Hospital
-
Contact:
- Min Hwan Kim
- Phone Number: +82-2-2228-8133
- Email: gemgoon3691@yuhs.ac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with recurrent, metastatic, or unresectable ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed cytologically or histologically as mucinous cancer.
*Subjects who are metastatic (stage IV) or mucinous ovarian cancer that cannot be surgically resected at diagnosis may have undergone cytoreductive surgery prior to systemic chemotherapy. It is appropriate for participation in this study if there are residual lesions after surgery and other selection criteria are met.
- Mucous tumors of gastrointestinal origin should be excluded by prior upper and lower intestinal endoscopy and pathologic immunohistochemical staining (CEA, SATB2, etc.).
Patients who have not received previous systemic chemotherapy for recurrent, metastatic, or unresectable ovarian, fallopian tube, or primary peritoneal cancer, or who have failed second-line or less systemic chemotherapy. However, immunotherapy alone (eg, anti-PD-1 or anti-PD-L1 immunotherapy) is not included in previous chemotherapy.
*Platinum susceptibility does not affect the selection/exclusion criteria for this trial.
- Informed consent
- Age more than 19 years old
- Patients with measurable lesions according to RECIST v1.1.
- ECOG Performance score 0-2
- Patients with adequate organ function
- Women of childbearing potential must either have a negative pregnancy test on a urine or serological test or consent to the use of an appropriate contraceptive method.
Exclusion Criteria:
- Patients who have previously received systemic chemotherapy, including oxaliplatin or irinotecan. *Previous treatment with bevacizumab is acceptable.
- Pregnant or breastfeeding women
- Patients who received chemotherapy, targeted small-molecule agents, or radiotherapy within 2 weeks prior to Day 1 of the study, or who have not yet recovered (Grade 1 or lower or baseline level) from a previously administered drug-induced adverse event.
- Active central nervous system (CNS) metastases and/or carcinoma meningitis.
- Patients with known aggravation within the past 3 years or other malignant tumors requiring aggressive treatment.
- Patients with moderate acute or chronic medical conditions or abnormal findings on examination, which are judged to affect the results of this study
- Infected with Human Immunodeficiency Virus (HIV) (HIV-1/2 antibody) infection or active hepatitis B (HBsAg positive and HBV DNA ≥100 copies/ml) or hepatitis C (anti-HCV antibody positive and HCV RNA detected) being)
- Clinically significant heart disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bevacizumab + modified FOLFIRINOX
Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
|
Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: up to 1 year
|
Objective response rate assessed using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for Intention-to-treatment group
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: up to 1 year
|
Progression-free survival assessed using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) and Kaplan-Meier Survival analysis
|
up to 1 year
|
Disease control rate
Time Frame: at 6 months
|
Disease control rate assessed using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for Intention-to-treatment group
|
at 6 months
|
Overall survival
Time Frame: up to 1 year
|
Overall survival assessed using Kaplan-Meier Survival analysis to check survival outcomes of Intention-to-treatment group
|
up to 1 year
|
Number of Participants With Adverse Events (CTCAE v5.0)
Time Frame: from the start to within 30 days of the final chemotherapy
|
Safety profiles assessed using Common Terminology Criteria for Adverse Events v5.0 (CTCAE v5.0)
|
from the start to within 30 days of the final chemotherapy
|
Patient reported outcomes
Time Frame: at the beginning and every 4 cycles of the treatment (each cycle is 14 days), up to 1 year
|
Patient reported outcomes assessed using EQ-5D
|
at the beginning and every 4 cycles of the treatment (each cycle is 14 days), up to 1 year
|
Patient reported outcomes
Time Frame: at the beginning and every 4 cycles of the treatment (each cycle is 14 days), up to 1 year
|
Patient reported outcomes assessed using EORTC QLQ-CIPN20
|
at the beginning and every 4 cycles of the treatment (each cycle is 14 days), up to 1 year
|
Febrile neutropenia prevention efficacy and safety profiles of Pegteograstim
Time Frame: from the start to within 30 days of the final chemotherapy
|
Pegteograstim efficacy and safety profiles assessed using Common Terminology Criteria for Adverse Events v5.0 (CTCAE v5.0)
|
from the start to within 30 days of the final chemotherapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Min Hwan Kim, Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Fallopian Tube Diseases
- Neoplasms, Cystic, Mucinous, and Serous
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Adenocarcinoma, Mucinous
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
- Folfirinox
Other Study ID Numbers
- 4-2021-1776
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fallopian Tube Cancer
-
OncoMed Pharmaceuticals, Inc.CompletedCancer Ovaries | Cancer Peritoneal | Cancer, Fallopian TubeUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditionsUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Istituto Di Ricerche Farmacologiche Mario Negri; Foundation MedicineRecruitingAdvanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube CancerItaly
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Active, not recruitingStage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterGenentech, Inc.CompletedOvarian Cancer | Peritoneal Cancer | Fallopian Tubes CancerUnited States
-
Centre Jean PerrinCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity CancerFrance
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions
-
Genentech, Inc.CompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Precision TherapeuticsCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
Clinical Trials on Bevacizumab + modified FOLFIRINOX
-
Yonsei UniversityRecruitingResectable Pancreatic AdenocarcinomaKorea, Republic of
-
Second Affiliated Hospital, School of Medicine,...CompletedPancreatic Cancer | Surgery--Complications | Chemotherapy EffectChina
-
University Health Network, TorontoPancreatic Cancer CanadaActive, not recruitingResectable Pancreatic CancerCanada
-
Yonsei UniversityCompletedPancreatic Ductal Adenocarcinoma
-
AbbVieActive, not recruitingPancreatic CancerUnited States, Australia, Israel, Korea, Republic of, Puerto Rico, Spain
-
Angiodynamics, Inc.RecruitingStage III Pancreatic CancerUnited States
-
University of Michigan Rogel Cancer CenterWithdrawnMetastatic Pancreatic AdenocarcinomaUnited States
-
Emory UniversityCompletedPancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Second Affiliated Hospital, School of Medicine,...RecruitingChemotherapy Effect | Pancreatic Adenocarcinoma MetastaticChina
-
Centre Georges Francois LeclercActive, not recruiting